TransMedics Ebitda from 2010 to 2025

TMDX Stock  USD 68.84  1.49  2.12%   
TransMedics EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA is likely to outpace its year average in 2025. During the period from 2010 to 2025, TransMedics EBITDA regression line of annual values had r-squared of  0.31 and arithmetic mean of (11,277,603). View All Fundamentals
 
EBITDA  
First Reported
2018-03-31
Previous Quarter
13 M
Current Value
16.2 M
Quarterly Volatility
9.6 M
 
Covid
Check TransMedics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TransMedics' main balance sheet or income statement drivers, such as Interest Expense of 15.1 M, Selling General Administrative of 177 M or Operating Income of 39.4 M, as well as many indicators such as Price To Sales Ratio of 4.46, Dividend Yield of 0.0 or PTB Ratio of 9.52. TransMedics financial statements analysis is a perfect complement when working with TransMedics Valuation or Volatility modules.
  
Check out the analysis of TransMedics Correlation against competitors.

Latest TransMedics' Ebitda Growth Pattern

Below is the plot of the Ebitda of TransMedics Group over the last few years. It is TransMedics' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TransMedics' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

TransMedics Ebitda Regression Statistics

Arithmetic Mean(11,277,603)
Geometric Mean25,535,091
Coefficient Of Variation(292.43)
Mean Deviation21,202,645
Median(22,555,000)
Standard Deviation32,979,587
Sample Variance1087.7T
Range111.9M
R-Value0.56
Mean Square Error806T
R-Squared0.31
Significance0.03
Slope3,846,472
Total Sum of Squares16314.8T

TransMedics Ebitda History

202573.4 M
202469.9 M
2023-7.6 M
2022-29 M
2021-38.5 M
2020-23.2 M
2019-28.8 M

About TransMedics Financial Statements

TransMedics investors use historical fundamental indicators, such as TransMedics' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TransMedics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA69.9 M73.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TransMedics Stock Analysis

When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.